Literature DB >> 19835738

Testicular cancer: a prototypic tumor of young adults.

Brandon Hayes-Lattin1, Craig R Nichols.   

Abstract

Testicular cancer is the most common solid tumor among males in the 20- to 39-year age range. Moreover, testicular cancer has unique biological associations, clinical features, and psychosocial impacts that establish this tumor as a prototypic malignancy of young adults. The biology of testicular germ cell tumors after puberty is distinctive. Epidemiologic patterns of testicular cancer suggest etiologic factors that may be congenital, racial, and geographic. The clinical management of a cancer common among young adults, but rare among adults in general, requires expertise so as not to jeopardize the high rates of survivorship associated with modern therapy. The concurrent but separate development of staging, prognostic systems, and treatment recommendations between the fields of pediatric and adult oncology highlights the need for increased integration and cooperation across these subspecialties. The high rate of survival, combined with the need for long-term monitoring for relapse or late effects, demonstrates the challenge of delivering longitudinal care in this mobile and active young adult population.

Entities:  

Mesh:

Year:  2009        PMID: 19835738      PMCID: PMC2796329          DOI: 10.1053/j.seminoncol.2009.07.006

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  25 in total

1.  Klinefelter's syndrome associated with mediastinal germ cell neoplasms.

Authors:  C R Nichols; N A Heerema; C Palmer; P J Loehrer; S D Williams; L H Einhorn
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

2.  Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis.

Authors:  D C Doll; A F List; F A Greco; J D Hainsworth; K R Hande; D H Johnson
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

3.  Testicular tumors following orchiopexy.

Authors:  J A Dow; F K Mostofi
Journal:  South Med J       Date:  1967-02       Impact factor: 0.954

4.  Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.

Authors:  R de Wit; J T Roberts; P M Wilkinson; P H de Mulder; G M Mead; S D Fosså; P Cook; L de Prijck; S Stenning; L Collette
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

5.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

Authors:  S W Thompson; L E Davis; M Kornfeld; R D Hilgers; J C Standefer
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

6.  Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

Authors:  R R Reddel; R F Kefford; J M Grant; A S Coates; R M Fox; M H Tattersall
Journal:  Cancer Treat Rep       Date:  1982-01

7.  Semen analysis in testicular cancer and Hodgkin's disease: pre- and post-treatment findings and implications for cryopreservation.

Authors:  W F Hendry; J Stedronska; C R Jones; C A Blackmore; A Barrett; M J Peckham
Journal:  Br J Urol       Date:  1983-12

8.  Familial testicular cancer and urogenital developmental anomalies.

Authors:  D J Tollerud; W A Blattner; M C Fraser; L M Brown; L Pottern; E Shapiro; A Kirkemo; T H Shawker; N Javadpour; K O'Connell
Journal:  Cancer       Date:  1985-04-15       Impact factor: 6.860

9.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.

Authors:  S D Williams; R Birch; L H Einhorn; L Irwin; F A Greco; P J Loehrer
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

10.  A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party.

Authors:  A Horwich; R T Oliver; P M Wilkinson; G M Mead; S J Harland; M H Cullen; J T Roberts; S D Fossa; D P Dearnaley; E Lallemand; S P Stenning
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more
  32 in total

1.  Trans- and extraperitoneal retroperitoneal lymph node dissection (RPLND) in the treatment for nonseminomatous germ cell testicular tumors (NSGCT): a single Chinese center's retrospective analysis.

Authors:  Shiyu Tong; Minfeng Chen; Xiongbing Zu; Yuan Li; Wei He; Ye Lei; Wentao Liu; Lin Qi
Journal:  Int Urol Nephrol       Date:  2013-09-01       Impact factor: 2.370

2.  Testicular cancer survivors' supportive care needs and use of online support: a cross-sectional survey.

Authors:  Jacqueline L Bender; David Wiljer; Matthew J To; Philippe L Bedard; Peter Chung; Michael A S Jewett; Andrew Matthew; Malcolm Moore; Padraig Warde; Mary Gospodarowicz
Journal:  Support Care Cancer       Date:  2012-03-03       Impact factor: 3.603

3.  AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway.

Authors:  Hailiang Xu; Yunyun Feng; Zhankui Jia; Jinjian Yang; Xueren Lu; Jun Li; Mingliang Xia; Chunru Wu; Yonggang Zhang; Jianhua Chen
Journal:  Oncol Lett       Date:  2017-05-19       Impact factor: 2.967

4.  Testicular Cancer Awareness and Knowledge: Is It the Same? Exploratory Study in a Mixed-Gender Population.

Authors:  Isaac Campos Braga; João Cabral; Nuno Louro; José LaFuente de Carvalho
Journal:  J Cancer Educ       Date:  2017-03       Impact factor: 2.037

5.  Regulatory network of microRNAs and genes in testicular cancer.

Authors:  Yansong Zhao; Zhiwen Xu; Ning Wang; Shang Wang
Journal:  Oncol Lett       Date:  2016-08-24       Impact factor: 2.967

6.  The stem cell factor (SCF)/c-KIT signalling in testis and prostate cancer.

Authors:  Henrique J Cardoso; Marília I Figueira; Sílvia Socorro
Journal:  J Cell Commun Signal       Date:  2017-06-27       Impact factor: 5.782

7.  Dynamic contrast-enhanced and diffusion-weighted MR imaging in the characterisation of small, non-palpable solid testicular tumours.

Authors:  Lucia Manganaro; Matteo Saldari; Carlotta Pozza; Valeria Vinci; Daniele Gianfrilli; Ermanno Greco; Giorgio Franco; Maria Eleonora Sergi; Michele Scialpi; Carlo Catalano; Andrea M Isidori
Journal:  Eur Radiol       Date:  2017-08-30       Impact factor: 5.315

Review 8.  Gynecomastia and hormones.

Authors:  Andrea Sansone; Francesco Romanelli; Massimiliano Sansone; Andrea Lenzi; Luigi Di Luigi
Journal:  Endocrine       Date:  2016-05-04       Impact factor: 3.633

9.  Disparities in Adolescent and Young Adult Survival After Testicular Cancer Vary by Histologic Subtype: A Population-Based Study in California 1988-2010.

Authors:  Mindy C DeRouen; Mahasin Mujahid; Sandy Srinivas; Theresa H M Keegan
Journal:  J Adolesc Young Adult Oncol       Date:  2015-11-18       Impact factor: 2.223

Review 10.  Epigenetic drugs and their molecular targets in testicular germ cell tumours.

Authors:  Daniel Nettersheim; Hubert Schorle; Sina Jostes
Journal:  Nat Rev Urol       Date:  2019-04       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.